Quang X. Pham - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Quang X. Pham has filed 10 SEC Form 4 filings across 1 company in the last 90 days - selling. Lifetime open-market sales: $701K.
Profile
Quang X. Pham is Chairman and CEO at Cadrenal Therapeutics, Inc. (CVKD). Pham has reported 18 insider filings with the SEC since 2025. The most recent filing was in July 2026.
| Role | Chairman and CEO, Director, 10% Owner |
|---|---|
| Notability | 50/100 |
Board memberships
- Cadrenal Therapeutics, Inc.
Reported roles
- Chairman and CEO
Awards & honors
- CEO of Cadrenal Therapeutics
- Chairman of Cadrenal Therapeutics
- Director at Cadrenal Therapeutics
Trading Pattern
InsiderAlpha's records for Quang X. Pham go back to 2025: 16 primary Form 4 filings, an average of 8.0 per year. 27 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Career & Filing History
Every role Quang X. Pham has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Chairman and CEO, Director, 10% Owner at Cadrenal Therapeutics, Inc. (CVKD) - 1 filing, 2026
- Chairman, CEO and Interim CFO, Director, 10% Owner at Cadrenal Therapeutics, Inc. (CVKD) - 5 filings, 2026
- CEO and Chairman, Director, 10% Owner at Cadrenal Therapeutics, Inc. (CVKD) - 10 filings, 2025 to 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 7.4K | $3.03 | $22K |
| 2026-06-27 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 9.0K | $3.05 | $28K |
| 2026-06-27 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 2.1K | $3.00 | $6K |
| 2026-06-24 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 2.3K | $3.20 | $7K |
| 2026-06-24 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 9.2K | $3.55 | $33K |
| 2026-06-18 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 513 | $3.16 | $2K |
| 2026-06-18 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.6K | $3.18 | $11K |
| 2026-06-16 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.7K | $3.58 | $13K |
| 2026-06-16 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 13.0K | $3.94 | $51K |
| 2026-06-16 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 1.5K | $4.12 | $6K |
| 2026-06-11 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.5K | $4.21 | $15K |
| 2026-06-11 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 13.0K | $4.06 | $53K |
| 2026-06-11 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 5.9K | $4.38 | $26K |
| 2026-06-05 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 2.1K | $4.42 | $9K |
| 2026-06-05 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.9K | $4.41 | $17K |
| 2026-06-05 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 2.3K | $4.26 | $10K |
| 2026-06-03 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 349 | $4.46 | $2K |
| 2026-06-03 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 303 | $5.01 | $2K |
| 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.0K | $4.93 | $15K |
| 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | S - Open-market sale [10b5-1] | 3.3K | $5.28 | $17K |
Companies - Last 90 Days
- Cadrenal Therapeutics, Inc. (CVKD) - 10 filings, last 2026-07-02
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Quang X. Pham has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Matthew K. Szot - $397K of CVKD open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- R01 Fund LP
- RA CAPITAL MANAGEMENT, L.P.
- Bradley Louis Radoff
- RBC Global Asset Management (U.S.) Inc.
- Redmile Group, LLC
- Andrew Phillips Reed
- Daniel Reis-Faria
- RiverNorth Financial Holdings, LLC
Frequently Asked Questions
Who is Quang X. Pham?
Quang X. Pham is Chairman and CEO at Cadrenal Therapeutics, Inc. (CVKD). Pham has reported 18 insider filings with the SEC since 2025. The most recent filing was in July 2026.…
How many SEC Form 4 filings has Quang X. Pham submitted recently?
10 primary Form 4 filings in the last 90 days, covering 1 company.
Has Quang X. Pham been buying or selling stock?
Recorded transactions: 0 open-market purchases and 33 open-market sales ($701K) across all tracked filings.
Where can I see all of Quang X. Pham's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Quang X. Pham profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.